Specific Biologics
Developing Dualase® gene-editing platform for in vivo treatment of genetic diseases, starting with C9ORF72-associated ALS.
Website: https://www.specificbiologics.com/
Cover Block
Open sources
| Field | Value |
|---|---|
| Name | Specific Biologics |
| Tagline | Developing Dualase® gene-editing platform for in vivo treatment of genetic diseases, starting with C9ORF72-associated ALS. |
| Headquarters | Toronto, Canada [Crunchbase, retrieved 2026] |
| Founded | 2021 [Crunchbase, retrieved 2026] |
| Stage | Series A [Crunchbase, retrieved 2026] |
| Business Model | Other |
| Industry | Healthtech |
| Technology | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout [Western University Schulich Medicine & Dentistry, Nov 2025] |
| Funding Label | Series A |
| Total Disclosed | Approximately $35,000,000 [PR Newswire, Nov 2026] |
Links
Open sources
- Website: https://www.specificbiologics.com/
What an Investor Needs First
PUBLIC Specific Biologics is a Toronto gene-editing company building Dualase®, an in vivo platform for genetic disease, and it merits investor attention now because it has moved from academic spinout status into a newly financed clinical-development push in C9ORF72-associated ALS [PR Newswire, Nov 2026] [Western University Schulich Medicine & Dentistry, Nov 2025]. The company was founded in 2021 out of research led by Western University biochemistry professor David Edgell, with Brent Stead serving as co-founder and CEO; public materials tie the origin story closely to Edgell's underlying gene-editing work and Stead's blend of biochemistry training and business education [Private Equity International, Dec 2021] [Western University Schulich Medicine & Dentistry, Nov 2025].
The central product claim is that Dualase uses a dual-cleaving nuclease and targeted RNA-templated repair to enable precise edits, deletions, and insertions in human cells, with the company's lead program aimed at collapsing toxic DNA repeat expansions in the most common genetic cause of ALS [bioRxiv, Apr 2024] [PackGene Biotech, Mar 2026]. That is the technical point to watch: the differentiation rests less on a broad platform narrative than on whether this repair mechanism can translate into safe, reproducible in vivo performance in a difficult neurological indication [PR Newswire, Nov 2026] [Specific Biologics, retrieved 2026].
The team reads like a classic academic-commercial bridge. Edgell remains the scientific anchor, Stead leads the company, Odi Israel is identified publicly as co-founder and COO, and the company added experienced gene-editing operators Brad Geddes and Paul Alloway in 2026, while board chair Paul Hastings brings prior biotechnology leadership experience [Crunchbase, retrieved 2026] [Specific Biologics on LinkedIn, retrieved 2026] [The Globe and Mail / Canadian Press, Nov 2026] [adMare BioInnovations, retrieved 2026].
On capital formation, the public record shows seed backing in 2021 from Lumira Ventures and adMare BioInnovations, support from the Cystic Fibrosis Foundation, a C$1.8 million grant in March 2026 from Genome Canada and Ontario Genomics, and a US$35 million Series A in November 2026 led by Hatteras Venture Partners with participation from several specialist investors [Private Equity International, Dec 2021] [BioSpace, retrieved 2026] [Cision / Newswire, Mar 2026] [PR Newswire, Nov 2026]. The business model is still best understood as a venture-backed therapeutic development company rather than a software or services business, with value creation tied to preclinical and early clinical de-risking of its lead program [Crunchbase, retrieved 2026] [PR Newswire, Nov 2026].
Over the next 12 to 18 months, the evidence threshold is straightforward: investors should watch for translational data, regulatory progress toward the adaptive Phase I/II plan, and any clearer read on delivery, biomarkers, and whether Dualase can show signal in vivo beyond company-level platform claims [PR Newswire, Nov 2026] [Cision / Newswire, Mar 2026]. The company has assembled credible early ingredients, but the investability of the story still turns on biology and execution more than financing optics.
Partially corroborated -- This section relies on a mix of independent reporting, academic publication, and company-issued materials; several core product and clinical-development claims remain primarily company-sourced or only partially corroborated.
Taxonomy Snapshot
| Axis | Value |
|---|---|
| Stage | Series A |
| Business Model | Other |
| Industry / Vertical | Healthtech |
| Technology Type | Biotech / Life Sciences |
| Geography | North America |
| Growth Profile | Venture Scale |
| Founding Team | Academic Spinout |
| Funding | Total disclosed approximately US$35,000,000 |
Inside the Company
PUBLIC Specific Biologics is a Toronto-based biotechnology company founded in 2021 and focused on in vivo gene editing through its Dualase platform [Crunchbase, retrieved 2026] [Specific Biologics, retrieved 2026]. Public company materials describe the work in plain terms: editing disease-causing DNA changes inside the body rather than in cells modified outside it [Specific Biologics, retrieved 2026]. That framing matters because it places the company in a narrower, technically demanding part of gene editing, one where delivery and repair biology are part of the core product claim, not an afterthought [Specific Biologics, retrieved 2026].
The founding team publicly listed across company and profile sources includes Brent Stead, David Edgell, and Odi Israel [Crunchbase, retrieved 2026]. The company website presents Dualase as the central platform, while Crunchbase places the business at Series A stage as of 2026 [Specific Biologics, retrieved 2026] [Crunchbase, retrieved 2026]. On chronology, the public record is still short but usable: the company was founded in 2021, built around the Dualase gene-editing platform, and by 2026 had advanced to a disclosed Series A financing that positioned the company as a venture-backed therapeutic platform rather than a purely academic project [Crunchbase, retrieved 2026] [Specific Biologics, retrieved 2026].
Verified against public records -- Confirmed by Crunchbase and the company website.
Under the Hood
MIXED
The core product story is narrow, which is usually a better sign in therapeutics than a broad platform pitch. Specific Biologics is developing Dualase®, a gene-editing platform intended to treat genetic disease inside the body, with its lead application focused on C9ORF72-associated amyotrophic lateral sclerosis, or ALS [PR Newswire, Nov 2026] [Specific Biologics, retrieved 2026] [The Globe and Mail / Canadian Press, Nov 2026]. Public materials describe Dualase as a dual-cleaving nuclease designed to make precise edits, deletions, and insertions in human cells by using targeted RNA-templated repair and endogenous DNA-repair pathways, rather than relying on separately delivered repair machinery [bioRxiv, Apr 2024] [Specific Biologics, retrieved 2026] [The Org, retrieved 2026].
The evidence base is strongest on platform intent and lead indication, and weaker on claims of technical distinctiveness. Company materials say the system can be delivered in vivo and that the pipeline spans CNS, lung, and liver programs, with delivery approaches including single AAV and lipid nanoparticle or polymer-encapsulated all-RNA formats [Specific Biologics, retrieved 2026]. Those modality and pipeline statements are still company-sourced, so they should be read as development direction rather than validated performance. What is corroborated externally is that the current financing is meant to push the lead ALS candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II study, which gives the platform a visible translational milestone rather than leaving it at the discovery stage [PR Newswire, Nov 2026] [FinSMEs, Nov 2026].
Earlier work appears to have extended beyond ALS, particularly into cystic fibrosis-related delivery research. Western University reported that Cystic Fibrosis Foundation-backed work explored an inhalable nanoparticle approach intended to reach lung cells, which aligns with the company's public positioning around in vivo editing and lung applications [Western University Schulich Medicine & Dentistry, Nov 2025]. The practical read is that Specific Biologics is presenting as a platform company, but public proof today is still concentrated in one named program and a small set of supporting technical claims.
Partially corroborated -- Core product and indication are corroborated by company materials, press coverage, and a preprint, but several modality and pipeline details remain primarily company-sourced.
Market Research
Open sources
Gene editing remains one of the few parts of biotech where financing, clinical ambition, and platform breadth can all move at once, which is why the market matters now even without a public revenue line from the company itself. For Specific Biologics, the immediate commercial context is narrower than the broad gene-editing narrative: the lead program is aimed at C9ORF72-associated amyotrophic lateral sclerosis, or ALS, and the company says its Series A is intended to carry that program through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II study [PR Newswire, Nov 2026]. Public sources also state there are currently no approved therapies for C9ORF72-associated ALS, which sharpens the unmet-need case even if it does not, on its own, establish market size [BIOTECanada, Nov 2026].
The usual TAM, SAM, and SOM framework is not well supported by the source set here. No named third-party market report on C9ORF72 ALS, in vivo gene editing, or the repeat-expansion disease segment was provided in the research packet, so any hard sizing figure would risk false precision. The more defensible read is that Specific Biologics sits at the intersection of several adjacent markets with established investor attention: in vivo gene editing, rare-disease therapeutics, and neurodegenerative disease drug development, with earlier company work also pointing toward pulmonary delivery and cystic-fibrosis-related applications [Western University Schulich Medicine & Dentistry, Nov 2025] [Specific Biologics, retrieved 2026].
A small evidence map is more useful here than a speculative market model.
| Market lens | What the public sources support | Relevance to Specific Biologics |
|---|---|---|
| Lead indication market | C9ORF72-associated ALS has no approved therapies cited in public sources [BIOTECanada, Nov 2026] | Supports unmet need for the initial wedge |
| Platform market | Dualase is being developed as an in vivo gene-editing platform, not a single-asset company [PR Newswire, Nov 2026] [Specific Biologics, retrieved 2026] | Expands potential beyond one indication if delivery and safety translate |
| Adjacent disease areas | Earlier work referenced cystic fibrosis and hard-to-treat neurological diseases [Western University Schulich Medicine & Dentistry, Nov 2025] | Suggests optionality across lung and CNS settings |
| Delivery and tooling layer | A 2026 grant funded a machine-learning platform to accelerate Dualase-based therapeutic development [Cision / Newswire, Mar 2026] | Indicates the company is investing in development infrastructure, not only a single program |
from the public record is that the addressable opportunity should be read as platform-shaped rather than as a single orphan indication. That can widen the upside, but it also pushes key diligence questions from market size toward translatability, delivery, and regulatory path.
Demand drivers in the cited research are straightforward and unusually concrete. The first is untreated disease burden in the lead indication, with the company and BIOTECanada both pointing to the absence of approved therapies for C9ORF72-associated ALS [PR Newswire, Nov 2026] [BIOTECanada, Nov 2026]. The second is modality pull: Specific Biologics is positioning Dualase around in vivo editing, which, if it proves clinically workable, could be more operationally attractive than ex vivo approaches for some tissues because treatment happens inside the body rather than through cell extraction and reinfusion [Specific Biologics, retrieved 2026] [bioRxiv, Apr 2024]. The third is investor and grant support across stages, from 2021 seed financing through a C$1.8 million development grant in March 2026 and a US$35 million Series A in November 2026, suggesting that both private capital and public innovation funders see continued interest in the category [Private Equity International, Dec 2021] [Cision / Newswire, Mar 2026] [PR Newswire, Nov 2026].
The adjacent and substitute markets are also worth naming plainly. Adjacent markets include broader gene-editing therapeutics for CNS, lung, and liver disease, although the company-originated pipeline framing around those organs should be treated cautiously because it is not independently corroborated [Specific Biologics, retrieved 2026]. Substitute markets include antisense oligonucleotides, small molecules, and other neurodegenerative-disease treatment approaches that do not require permanent genomic modification, as well as competing editing architectures that rely on different repair mechanisms. The practical implication is that Specific Biologics does not need to win all of gene editing to matter commercially, but it likely does need to show a differentiated safety and delivery profile in one high-need indication before platform breadth has market value.
Regulatory and macro forces cut both ways. On the supportive side, rare and severe genetic diseases continue to attract capital, academic partnerships, and patient-advocacy funding, with the Cystic Fibrosis Foundation and Genome Canada both appearing in the company's public funding history [Western University Schulich Medicine & Dentistry, Nov 2025] [Cision / Newswire, Mar 2026]. On the constraining side, in vivo gene-editing programs face a high evidence bar around off-target effects, delivery efficiency, and durability, and the current public materials do not provide clinical data that would answer those questions. That leaves the market case intact at a strategic level, but still early at the asset level.
Claim stands unchecked -- This section relies mainly on company-issued materials and adjacent public reporting, with no named third-party market-sizing report provided for TAM, SAM, or SOM.
Competition and Substitutes
MIXED Specific Biologics is positioned less against a clearly disclosed set of named direct peers, and more against the broader gene-editing and genetic-medicine stack that competes for the same clinical indications, delivery routes, investor attention, and translational talent [PR Newswire, Nov 2026] [Western University Schulich Medicine & Dentistry, Nov 2025].
The public record here is thinner than an investor would want, because the structured sources do not name direct company competitors for Specific Biologics' lead program or platform. That matters in a gene-editing context, where competition tends to sort into three layers rather than one. The first layer is incumbent therapeutic standard of care in ALS, which can remain commercially relevant even when it does not address the same mutation-specific biology. The second is other gene-editing or genetic-medicine developers pursuing in vivo correction, deletion, or silencing strategies in neurology and other monogenic disease settings. The third is adjacent substitute platforms, including companies built around delivery, manufacturing, or programmable nucleases, that can become partners in one cycle and competitive alternatives in the next [PR Newswire, Nov 2026] [bioRxiv, Apr 2024].
Within that map, Specific Biologics' stated wedge is relatively clear. It is developing Dualase®, described as a dual-cleaving gene-editing platform for in vivo treatment of genetic disease, initially focused on C9ORF72-associated ALS, and the company says the financing is intended to carry the lead candidate through initial clinical biomarker proof-of-concept in the first cohort of an adaptive Phase I/II study [PR Newswire, Nov 2026] [BIOTECanada, Nov 2026]. In practice, that places the company in a narrower competitive lane than broad platform stories: it is not yet competing on a disclosed multi-program commercial footprint, but on whether its editing architecture and delivery thesis can show an early human signal in a setting where there are currently no approved therapies for the specific C9ORF72-associated ALS indication it is targeting [BIOTECanada, Nov 2026] [PR Newswire, Nov 2026].
The present edge appears to come from talent formation and scientific origin more than from distribution or scale. The company emerged from Western University research associated with David Edgell, a biochemistry professor and scientific co-founder identified as the inventor of the underlying technique, while CEO Brent Stead combines a biochemistry PhD with business training, and the company added senior gene-editing operators Brad Geddes and Paul Alloway in 2026 [Western University Schulich Medicine & Dentistry, Nov 2025] [Schulich School of Medicine & Dentistry - Western University, 2026] [The Globe and Mail / Canadian Press, Nov 2026]. That mix can be durable if the platform's mechanistic claims translate into cleaner delivery, better edit outcomes, or a more usable safety profile. It is also perishable, because preclinical scientific differentiation in gene editing tends to lose value quickly if better-capitalized programs reach the clinic first or if delivery constraints narrow the practical advantage of the edit itself [bioRxiv, Apr 2024] [PR Newswire, Nov 2026].
Capital is a second, but more conditional, source of positioning. The company disclosed a US$35 million Series A in November 2026 led by Hatteras Venture Partners, with participation from Lumira Ventures, adMare BioInnovations, Genesys Capital, BDC Life Sciences Venture Fund, DeepWork Capital, and Seido Capital, after earlier seed backing and a C$1.8 million Genome Canada and Ontario Genomics grant tied to a machine-learning platform for Dualase-based therapeutics [PR Newswire, Nov 2026] [Private Equity International, Dec 2021] [Cision / Newswire, Mar 2026]. For a Canadian academic spinout, that is meaningful support. For an in vivo gene-editing company heading toward clinical work, it is still better read as enough capital to test the thesis than enough capital to own the category.
The company's main exposure is straightforward. It does not appear, from the cited public record, to own a disclosed commercial channel, pharmaceutical partnership, manufacturing network, or broad clinical portfolio that would insulate it if the lead ALS program slows [PR Newswire, Nov 2026] [Specific Biologics, retrieved 2026]. Its earlier work in cystic fibrosis and other hard-to-treat neurological disease areas suggests platform optionality, but optionality is not the same as competitive control, particularly in a field where delivery modality, regulatory sequencing, and clinical execution can outrank elegant mechanism [Western University Schulich Medicine & Dentistry, Nov 2025] [Specific Biologics, retrieved 2026]. That leaves the company more exposed to category-level competition from larger genetic-medicine groups and better funded in vivo editors, even when those peers are not named in the source set.
The most plausible 18-month scenario is therefore binary but not extreme. Winner if X is Specific Biologics, if the company can convert its Series A and academic-origin platform into credible early clinical biomarker proof-of-concept in C9ORF72-associated ALS, because a human signal in an indication with no approved therapies would move it from interesting platform story to clinically relevant contender [PR Newswire, Nov 2026] [BIOTECanada, Nov 2026]. Loser if Y is the broader class of small, pre-proof-of-concept editing spinouts, including Specific Biologics itself, if capital markets and partners continue to favor programs with clearer delivery validation, later-stage data, or repeatable clinical development infrastructure rather than earlier platform novelty alone [Private Equity International, Dec 2021] [PR Newswire, Nov 2026].
Opportunity
Upside case
PUBLIC The prize here is unusually large because success in a first in vivo gene-editing indication can create more than a single-asset biotech, it can create a reusable platform company with multiple shots on goal across severe genetic disease [PR Newswire, Nov 2026] [bioRxiv, Apr 2024].
The headline opportunity is not simply to move one ALS program into the clinic. It is to prove that Dualase can make precise edits, deletions, and insertions in human cells using targeted RNA-templated repair, then carry that editing logic into additional organs and indications over time [bioRxiv, Apr 2024] [Specific Biologics, retrieved 2026]. That outcome is still conditional, but it is not abstract. Public evidence shows a defined lead program in C9ORF72-associated ALS, stated plans to reach initial clinical biomarker proof-of-concept in an adaptive Phase I/II trial, and platform ambitions that already extend beyond a single tissue or delivery concept [PR Newswire, Nov 2026] [BIOTECanada, Nov 2026] [Specific Biologics, retrieved 2026].
The evidence base matters here because many platform stories stay broad and pre-clinical for too long. Specific Biologics has instead narrowed the first proof point to a named genetic driver in ALS, while separate public materials point to prior work in cystic fibrosis and to delivery concepts spanning single AAV and lipid nanoparticle or polymer-encapsulated all-RNA approaches [Western University Schulich Medicine & Dentistry, Nov 2025] [Specific Biologics, retrieved 2026]. If even one of those vectors becomes clinically actionable, the company could move from a disease-specific thesis to a modality thesis.
| Scenario | What happens | Catalyst | Why it's plausible |
|---|---|---|---|
| ALS wedge, platform follow-on | The lead C9ORF72-associated ALS program generates early biomarker evidence, giving the company a credible first clinical proof point and a financing path for broader platform expansion | Initial biomarker proof-of-concept in the first cohort of the planned adaptive Phase I/II study [PR Newswire, Nov 2026] | The company has already raised a US$35 million Series A specifically to advance this program, and public sources state there are no approved therapies for this subtype, which raises the value of a positive signal [PR Newswire, Nov 2026] [BIOTECanada, Nov 2026] |
| Multi-organ editing platform | Dualase shows enough precision and delivery flexibility to support programs in CNS, lung, and liver, turning one technical engine into a broader pipeline company | Reproducible preclinical or early clinical data that validates targeted RNA-templated repair across tissues [bioRxiv, Apr 2024] [Specific Biologics, retrieved 2026] | Public materials already describe a platform aimed at in vivo treatment and indicate programs or delivery approaches relevant to multiple organ systems, even if those programs remain early [Specific Biologics, retrieved 2026] [Western University Schulich Medicine & Dentistry, Nov 2025] |
| Partnered engine for rare disease | The company becomes a preferred partner for biopharma groups that want an in vivo editing approach for genetically defined diseases without building a platform internally | A collaboration following clinical or translational validation of Dualase in the lead indication [PR Newswire, Nov 2026] [Western University Schulich Medicine & Dentistry, Nov 2025] | The syndicate includes specialist life sciences investors, and the company retains an academic origin with translational support from Western University and genomics funders, which can be a credible setup for partnering if the first data set clears the bar [Private Equity International, Dec 2021] [Cision / Newswire, Mar 2026] |
The compounding mechanism would come from technical reuse rather than a classic software network effect. If the company can show that Dualase's editing architecture is reproducible, manufacturable, and compatible with more than one delivery modality, each additional program should become less about inventing a new editing system and more about matching target, tissue, and payload [bioRxiv, Apr 2024] [Specific Biologics, retrieved 2026]. The March 2026 Genome Canada and Ontario Genomics grant adds a second layer to that flywheel, because the company and Western University said the funding would support a machine-learning platform to accelerate development of Dualase-based therapeutics [Cision / Newswire, Mar 2026]. In plain terms, a validated editing mechanism plus better development tooling could shorten the path from one disease hypothesis to the next.
The size of the win is hard to anchor precisely from the public record because no valuation, revenue base, or direct public comparable is supplied in the source set. Still, one credible framing is that platform biotechs with clinical evidence in serious genetic disease can support enterprise values well beyond a single-asset company, and Specific Biologics has now assembled the ingredients investors usually look for before that rerating starts: a named lead indication, specialist syndicate support, translational academic roots, and a stated plan to reach human biomarker readouts [PR Newswire, Nov 2026] [Private Equity International, Dec 2021] [Western University Schulich Medicine & Dentistry, Nov 2025]. If the "ALS wedge, platform follow-on" scenario plays out, the company could plausibly become a high-value platform asset in neurogenetic and broader in vivo editing, with strategic value driven by repeatability across indications rather than by a single program alone (scenario, not a forecast).
Claim stands unchecked -- Material upside claims rely in part on company-issued statements and company website platform descriptions, with partial corroboration from Western University and bioRxiv.
Sources
Open sources
[Crunchbase, retrieved 2026] Specific Biologics - Crunchbase Company Profile & Funding | https://www.crunchbase.com/organization/specific-biologics
[Western University Schulich Medicine & Dentistry, Nov 2025] Gene Editing’s Next Frontier | https://www.schulich.uwo.ca/rapport/2025/people/gene_editings_next_frontier.html
[PR Newswire, Nov 2026] Specific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS | https://www.morningstar.com/news/pr-newswire/20261102to86258/specific-biologics-announces-oversubscribed-us-35-million-series-a-financing-to-advance-gene-editing-therapy-for-als
[Private Equity International, Dec 2021] Specific Biologics grabs first-time VC led by Lumira, adMare | https://www.privateequityinternational.com/specific-biologics-grabs-financing/
[bioRxiv, Apr 2024] Dualase enables targeted RNA-templated repair for precise edits, deletions and insertions in human cells | https://www.biorxiv.org
[PackGene Biotech, Mar 2026] Specific Biologics announces a $1.8M grant in support of its gene editing therapy development | https://www.packgene.com/news/specific-biologics-announces-a-1-8m-grant-in-support-of-its-gene-editing-therapy-development/
[Specific Biologics, retrieved 2026] Home | Specific Biologics | https://www.specificbiologics.com/
[Specific Biologics on LinkedIn, retrieved 2026] Specific Biologics on LinkedIn | https://www.linkedin.com/company/specific-biologics/
[The Globe and Mail / Canadian Press, Nov 2026] Can gene editing stop ALS? Toronto’s Specific Biologics advances therapy that could help some with fatal disease | https://ca.headtopics.com/news/can-gene-editing-stop-als-toronto-s-specific-biologics-89457604
[adMare BioInnovations, retrieved 2026] Specific Biologics Closes Seed Financing with Industry Leaders Lumira Ventures and adMare BioInnovations | https://www.admarebio.com/en/news-details/specific-biologics-closes-seed-financing-with-industry-leaders-lumira-ventures-and-admare-bioinnovations
[BioSpace, retrieved 2026] Cystic Fibrosis Foundation awards Specific Biologics $527,000 to advance gene-editing approach | https://www.biospace.com
[Cision / Newswire, Mar 2026] Genome Canada and Ontario Genomics Award Specific Biologics and Western University $1.8 Million Grant to Develop a Machine Learning Platform to Accelerate the Development of the Company’s Dualase®-based Therapeutics | https://www.newswire.ca/news/specific-biologics-inc./
[The Org, retrieved 2026] Specific Biologics | https://theorg.com/org/specific-biologics
[FinSMEs, Nov 2026] Specific Biologics Raises $35M in Series A Funding | https://www.finsmes.com/2026/11/specific-biologics-raises-35m-in-series-a-funding.html
[BIOTECanada, Nov 2026] Specific Biologics Announces Oversubscribed US$35 Million Series A Financing to Advance Gene-Editing Therapy for ALS | https://www.biotech.ca/specific-biologics-announces-oversubscribed-us35-million-series-a-financing-to-advance-gene-editing-therapy-for-als/
[Schulich School of Medicine & Dentistry - Western University, 2026] David Edgell | https://www.schulich.uwo.ca/biochem/people/bios/edgell_david.html
Articles about Specific Biologics
- The Cystic Fibrosis Foundation Funded Specific Biologics’ First Inhalable Delivery System — The Toronto spinout’s Dualase platform, designed to collapse toxic DNA repeats, is heading for its first human trial in a disease with no approved therapies.